Business Context and Reporting Period
This Form 8-K was filed by InMed Pharmaceuticals Inc. on December 13, 2022, reporting events that occurred on December 12, 2022. The filing addresses the appointment of an Interim Chief Financial Officer and the entry into a material definitive agreement to secure financial leadership services.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and service agreements.
- Monthly Service Fee: $9,750 for CFO services provided by Brio Financial Group.
- Equity Compensation: Options to acquire 1,400 Common Shares issued to Brio Financial Group (fully vested) and 1,400 Common Shares issued to Jonathan Tegge (vesting 1/12 per month over 12 months).
Material Changes
The primary material change is the appointment of Jonathan Tegge as Interim Chief Financial Officer, effective December 12, 2022. The Company is currently exploring options for a permanent full-time replacement. This appointment is facilitated through a new agreement with Brio Financial Group, replacing or supplementing previous internal financial leadership structures.
Outlook, Risks, and Management Commentary
Management Commentary: The Company has engaged Mr. Tegge through Brio Financial Group to provide senior financial leadership and bookkeeping services. The agreement term runs through December 31, 2023, with a termination clause allowing either party to end the agreement with 10 days' prior written notice.
Risks and Contingencies: The filing notes that the Company is in a transitional phase regarding its permanent CFO role. The reliance on an interim arrangement via a third-party vendor introduces dependency on the continued availability of Mr. Tegge and the stability of the Brio agreement.
Investor Verification Checklist
- Verify the total cost of the interim CFO arrangement, including the $9,750 monthly fee and the valuation of the 2,800 total options granted.
- Confirm the timeline and criteria for the search for a permanent Chief Financial Officer.
- Review the full text of the BRIO Agreement (Exhibit 10.1) and Consulting Agreement (Exhibit 10.2) for additional termination clauses or performance conditions not summarized in the 8-K.
- Check subsequent filings to determine if the interim arrangement was extended or if a permanent CFO was appointed before the December 31, 2023, expiration date.